These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
155 related articles for article (PubMed ID: 24120548)
1. Distribution of invasive meningococcal B disease in Italian pediatric population: implications for vaccination timing. Azzari C; Canessa C; Lippi F; Moriondo M; Indolfi G; Nieddu F; Martini M; de Martino M; Castiglia P; Baldo V; Resti M; Vaccine; 2014 Feb; 32(10):1187-91. PubMed ID: 24120548 [TBL] [Abstract][Full Text] [Related]
2. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy. Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931 [TBL] [Abstract][Full Text] [Related]
3. Epidemiology of invasive meningococcal B disease in Australia, 1999-2015: priority populations for vaccination. Archer BN; Chiu CK; Jayasinghe SH; Richmond PC; McVernon J; Lahra MM; Andrews RM; McIntyre PB; Med J Aust; 2017 Nov; 207(9):382-387. PubMed ID: 29092704 [TBL] [Abstract][Full Text] [Related]
4. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Ladhani SN; Flood JS; Ramsay ME; Campbell H; Gray SJ; Kaczmarski EB; Mallard RH; Guiver M; Newbold LS; Borrow R Vaccine; 2012 May; 30(24):3710-6. PubMed ID: 22429756 [TBL] [Abstract][Full Text] [Related]
6. Changing epidemiology of meningococcal invasive disease in the Czech republic caused by new clone Neisseria meningitidis C:2a:P1.2(P1.5), ET-15/37. Krizova P; Musilek M Cent Eur J Public Health; 1995 Nov; 3(4):189-94. PubMed ID: 8903519 [TBL] [Abstract][Full Text] [Related]
7. Health and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programme. Tirani M; Meregaglia M; Melegaro A PLoS One; 2015; 10(4):e0123383. PubMed ID: 25874805 [TBL] [Abstract][Full Text] [Related]
8. Present situation and new perspectives for vaccination against Neisseria meningitidis in Tuscany, Central Italy. Bechini A; Levi M; Boccalini S; Tiscione E; Ceccherini V; Taddei C; Balocchini E; Bonanni P J Prev Med Hyg; 2012 Jun; 53(2):61-7. PubMed ID: 23240162 [TBL] [Abstract][Full Text] [Related]
9. Epidemiology of pediatric meningitis caused by Haemophilus influenzae B, Streptococcus pneumoniae and Neisseria meningitidis in Israel. Dagan R Isr J Med Sci; 1994; 30(5-6):351-5. PubMed ID: 8034481 [TBL] [Abstract][Full Text] [Related]
10. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci. Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907 [TBL] [Abstract][Full Text] [Related]
11. [Evolution of meningococcal infection among infant population in the autonomous community of Valencia (1996-2000). Effectiveness of A+C meningococcal vaccination]. Goicoechea Sáez M; Fullana Montoro AM; Momparler Carrasco P; Redondo Gallego MJ; Brines Solanes J; Bueno Cañigral FJ Rev Esp Salud Publica; 2003; 77(1):125-42. PubMed ID: 12696392 [TBL] [Abstract][Full Text] [Related]
12. Meningococcal vaccine evolution. Bona G; Guidi C J Prev Med Hyg; 2012 Sep; 53(3):131-5. PubMed ID: 23362617 [TBL] [Abstract][Full Text] [Related]
13. Epidemiology of bacterial meningitis in Niamey, Niger, 1981-96. Campagne G; Schuchat A; Djibo S; Ousséini A; Cissé L; Chippaux JP Bull World Health Organ; 1999; 77(6):499-508. PubMed ID: 10427935 [TBL] [Abstract][Full Text] [Related]
14. Neisseria meningitidis B vaccines. Panatto D; Amicizia D; Lai PL; Gasparini R Expert Rev Vaccines; 2011 Sep; 10(9):1337-51. PubMed ID: 21919622 [TBL] [Abstract][Full Text] [Related]
15. Culture and Real-time Polymerase Chain reaction sensitivity in the diagnosis of invasive meningococcal disease: Does culture miss less severe cases? Guiducci S; Moriondo M; Nieddu F; Ricci S; De Vitis E; Casini A; Poggi GM; Indolfi G; Resti M; Azzari C PLoS One; 2019; 14(3):e0212922. PubMed ID: 30865671 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of a vaccination programme for an epidemic of meningococcal B in New Zealand. Arnold R; Galloway Y; McNicholas A; O'Hallahan J Vaccine; 2011 Sep; 29(40):7100-6. PubMed ID: 21803101 [TBL] [Abstract][Full Text] [Related]
17. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Cano R; Larrauri A; Mateo S; Alcalá B; Salcedo C; Vázquez JA Euro Surveill; 2004 Jul; 9(7):11-5. PubMed ID: 15318008 [TBL] [Abstract][Full Text] [Related]
18. Advances towards the prevention of meningococcal B disease: a multidimensional story. Roderick M; Finn A J Infect; 2014 Jan; 68 Suppl 1():S76-82. PubMed ID: 24139188 [TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of meningococcal serogroup B childhood vaccination in Ontario, Canada. Tu HA; Deeks SL; Morris SK; Strifler L; Crowcroft N; Jamieson FB; Kwong JC; Coyte PC; Krahn M; Sander B Vaccine; 2014 Sep; 32(42):5436-46. PubMed ID: 25131732 [TBL] [Abstract][Full Text] [Related]
20. Meningococcal disease in catalonia 1 year after mass vaccination campaign with meningococcal group C polysaccharide vaccine. Cardeñosa N; Domínguez A; Martínez A; Alvarez J; Pañella H; Godoy P; Minguell S; Camps N; Vázquez JA; Infection; 2003 Dec; 31(6):392-7. PubMed ID: 14735381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]